Navigation Links
CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda

CAMBRIDGE, England, February 23, 2010 /PRNewswire/ -- From its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer.

Under the terms of the new agreement, CellCentric will receive from Takeda Pharmaceutical Company Limited an upfront payment and pre-clinical and clinical milestones, in addition to royalties. Based on the royalties and milestones defined, the overall deal could be worth in excess of $200m to CellCentric over the course of the agreement.

This is a pioneering deal for the emerging area of epigenetics, demonstrating the commercial interest in novel epigenetic targets beyond HDACs (histone deacetylases) and DNMTs (DNA methyltransferases ). Therapeutic research will be initiated by Takeda's Research Group. Development of molecules stemming from this agreement will be completed by Millennium: The Takeda Oncology Company, which is responsible for Takeda's global oncology development strategy.

Many diseases including cancer involve a loss of cell fate control. In many cases this is associated with aberrant epigenetic changes to chromatin: dynamic modifications of DNA and its associated proteins, including histones. These epigenetic alterations are caused by a range of enzymes. Initial therapeutic interest has been focused on inhibiting HDAC and DNMTs. It has become increasingly clear that there are many other key epigenetic related enzymes that can be targeted and which may offer greater specificity of action. These include histone methyltransferases, demethylases and ubiquitin-related enzymes.

CellCentric has an innovation platform built upon relationships with over 30 world leading research labs in epigenetics. The company has identified and prioritised multiple next generation targets and runs a series of active drug discovery programmes from its centre in Cambridge, UK. As programmes move forward, CellCentric is able to gain continued benefit and support from multiple Principal Investigators within its network.

With an extensive portfolio and rich pipeline, CellCentric's strategy is to develop some target programmes through licences and collaborations with Pharmaceutical companies while retaining other programmes for development itself.

Dr Hiroyuki Odaka, General Manager of the Pharmaceutical Research Division of Takeda said "Epigenetics is an important area for novel oncology therapeutics. This new agreement demonstrates our commitment to researching and pioneering the best ways to treat cancer."

Dr Will West, CEO of CellCentric added "This licence is a strong endorsement of the way we are approaching innovation in epigenetics. This is an area that is no longer seen as just interesting, but as a necessity for pharmaceutical companies growing their armoury for tackling intractable diseases such as cancer".


CellCentric is a biotechnology company focused on epigenetics. Formed in 2004, it works with over 30 academic labs worldwide to identify, patent and commercialise product opportunities. CellCentric currently has 7 novel target discovery programmes ongoing, focused on cancer, as well as multiple projects related to reprogramming and epigenetic tools. For further details on the company, see:

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website

SOURCE CellCentric Ltd

Back to top
SOURCE CellCentric Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PSKW & Associates LLC Acquires Triax Media, Licenses Triax to Subsidiary, Centricity Group
2. TenX Biopharma Licenses Zanolimumab From Genmab
3. Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
4. Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation
5. SCOLR Pharma, Inc. Licenses Dietary Supplements
6. StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke
7. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
8. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
9. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
10. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
11. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... N.Y. , Nov. 25, 2015  Henry Schein, ... and services to office-based dental, medical and animal health ... (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion , ... broadest array of open solutions designed to help any ... Click here for a schedule of experts ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for ... of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ ...
(Date:11/27/2015)... ... , ... CBD College is proud to announce that on November ... to its Diagnostic Medical Sonography program. CBD College is honored to join this very ... and universities in the state of California make the cut. CBD College is officially ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... contact center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term ... fully supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of ...
(Date:11/26/2015)... Ashburn, VA (PRWEB) , ... November 26, 2015 ... ... Planners, an American Express Travel Representative. As a franchise owner, Somu now offers ... range of cruise, destination wedding packages, private cruise sales, as well as, cabin ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, ... in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted ... 8th through Wednesday, November 11th, 2015. The conference was held at the Hawaii ...
Breaking Medicine News(10 mins):